Prostate specific antigen (PSA) screening in some cases led to overdetection of prostate cancer, and now the same is occurring with recurrence.
NSAIDs target stem cells that have accumulated mutations that could lead to cancer development and a biochemical pathway that leads to apoptosis.
[Cancer Control] Castleman disease is a lesser seen lymphoproliferative disorder, which is characterized as either localized or multicentric, with differing treatments typically utilized for each type.
The Eastern Cooperative Oncology Group (ECOG) conducted a trial to investigate whether treatment deintensification was feasible in patients with HPV-associated cancer.
Fall Digital Issue
From Oncology Nurse Advisor
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Non-Hodgkin Lymphoma (NHL) Treatment Regimens: Burkitt Lymphoma
- Treatment Deintensification for HPV-Associated Oropharynx Cancer
- Diagnosis and Management of Castleman Disease
- Researchers Identify Mechanism by Which NSAIDs Prevent Colon Cancer
- Renal Cell Carcinoma More Advanced at Presentation in Younger Patients Than Those 21-30 Years Old
- Cancer Surgery Cost Not Linked with Hospital Volume
- Ramucirumab Plus Pemetrexed and Platinum Chemotherapy Shows Clinical Activity in Advanced Nonsquamous NSCLC
- For Advanced Ewing Sarcoma, Olaparib Alone Not Effective
- High Rates of Overdetection of Recurrence of Prostate Cancer
- Androgen Deprivation Therapy in Men with Prostate Cancer and Increased Risk of Cardiovascular Events